Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:EIGR

Eiger BioPharmaceuticals (EIGR) Stock Price, News & Analysis

Eiger BioPharmaceuticals logo

About Eiger BioPharmaceuticals Stock (NASDAQ:EIGR)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$1.30
$7.17
52-Week Range
N/A
Volume
137,800 shs
Average Volume
103,866 shs
Market Capitalization
$2.55 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive EIGR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Eiger BioPharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

EIGR Stock News Headlines

Remembering John Harlin, Eiger Legend
Critical AI announcement set to ignite AI 2.0
I just put together an urgent new presentation that you need to see right away. In short: I believe we are mere days away from a critical announcement from a key tech leader… One that will officially ignite “AI 2.0” – and potentially send a whole new class of stocks soaring.
Eiger Biopharmaceuticals Inc (EIGRQ)
Massive Rockfall on the North Face of the Eiger
Eiger BioPharmaceuticals, Inc. (EIGRQ)
72C.SG,0P00015QPW,0 (72C.SG)
See More Headlines

EIGR Stock Analysis - Frequently Asked Questions

Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) posted its quarterly earnings results on Thursday, November, 4th. The biotechnology company reported ($19.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($17.40) by $2.10. The biotechnology company had revenue of $3.04 million for the quarter, compared to the consensus estimate of $2.54 million. Eiger BioPharmaceuticals had a negative trailing twelve-month return on equity of 332.49% and a negative net margin of 590.80%.

Shares of Eiger BioPharmaceuticals reverse split before market open on Monday, January 8th 2024.The 1-30 reverse split was announced on Monday, January 8th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, January 8th 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that Eiger BioPharmaceuticals investors own include Enovix (ENVX), Rambus (RMBS), Ginkgo Bioworks (DNA), COMPASS Pathways (CMPS), Toast (TOST), Globant (GLOB) and Saia (SAIA).

Company Calendar

Last Earnings
11/04/2021
Today
7/18/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:EIGR
CIK
1305253
Employees
56
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($59.1592)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$96.78 million
Net Margins
-590.80%
Pretax Margin
-590.79%
Return on Equity
-332.49%
Return on Assets
-99.77%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
3.31
Quick Ratio
3.24

Sales & Book Value

Annual Sales
$15.77 million
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$37.68 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
1,480,000
Free Float
1,419,000
Market Cap
$2.55 million
Optionable
Optionable
Beta
1.83

Social Links

The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

This page (NASDAQ:EIGR) was last updated on 7/18/2025 by MarketBeat.com Staff
From Our Partners